37. Cohen BJ, Gandhi J, Clewley JP. Genetic variants of parvovirus B19 identified in the United Kingdom: Implications for diagnostic testing. J Clin Virol 2006; 36(2): 152-155.
38. Grabarczyk P, Kalińska A, Sulkowska E et al. False Negative Results in High Vire-mia Parvovirus B19-SamplesTested with Real-Time PCR. Pol J Microbiol2010; 59(2): 129-132.
39. Koppelman MHGM, Cuijpers HTM, Wessberg S et al. Multicenter evaluation of a commercial multiplex polymerase Chain reaction test for screening plasma donations for parvovirus 819 DNA and hepatitis A virus RNA.Transfusion 2012; 52(7): 1498-1508.
40. LeeT-H, Kleinman SH, Wen L et al. Distribution of parvovirus B19 DNA in blood compartments and persistence of virus in blood donors. Transfusion 2011; 51(9): 1896-1908.
41. Matsukura H, Shibata S, Tani Y et al. Persistent infection by human parvovirus B19 in qualified blood donors.Transfusion 2008; 48(5): 1036-1037.
42. Baylis SA, Ma L, Padley DJ et al. Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nudeic acid amplification technology (NAT)-based assays. Vox Sang 2012; 102(3): 204-211.
43. BaylisSA,ChudyM,BlumelJetal.Collaborativestudytoestablishareplacement World Health Organization International Standard for parvovirus BI 9 DNA nudeic acid amplification technology (N AT)-based assays. Vox Sang 2010; 98:441-446.
44. Siennicka J, Trzcińska A. Comparison of three enzyme immunoassays used todetect human parvovirus B19-specific IgM antibodies in sera of people su-spected of measles. Med Sci Monitor 2010; 16(5): 8R154-159.
45. Matsuda H, Sakaguchi K, Shibasaki T et al. Intrauterine therapy for parvovirus BI 9 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med 2005; 33:561-563.
46. Mace G, Sauvan M, Castaigne V et al. Clinical presentation and outcome of 20 fetuses with parvovirus B19 infection complicated by severe anemia and/or fetal hydrops. Prenat Diagn 2014; 34:1023-1030.